CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 37 enrolled
Drug / intervention
Losartan +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01989793
NCT01989793Phase 2Completed

A Study of Muscle Strength Maintenance in Older Adults

Johns Hopkins University·interventional·Posted Nov 21, 2013·Updated Jun 12, 2018

In Brief

A Phase 2 clinical trial evaluating Losartan and Placebo for Sarcopenia. Completed, enrolled 37 participants across 1 site.

Detailed Summary

This research study is being done to see whether losartan can prevent the decrease in strength associated with aging. Muscle loss is associated with aging and has multiple symptoms such as weakness, slowness, and fatigue (tiredness). Older adults with muscle weakness have a higher risk of falls and disability. In addition, the loss of independence for older adults can lead to a poorer quality of life. Recently, it was discovered that losartan, a medication commonly used to treat high blood pressure, had slowed the strength decline seen in older mice. In addition, it allowed injured mice skeletal muscle to heal faster. Therefore, we would like to see if losartan can do the same for older adults. Losartan is approved by the Food and Drug Administration (FDA) for the treatment of high blood pressure, heart failure, and to protect the kidneys in diabetic patients. Losartan is not FDA-approved to prevent the decrease in strength associated with aging. In this study, participants age 70 and older will be asked to take losartan or a placebo to see if losartan can help prevent loss of muscle strength. A placebo is a substance that looks like the study drug but that contains no active ingredients.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSarcopenia
CountriesUnited States

Timeline

Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedNov 21, 2013
Enrollment StartJul 1, 2013
Primary CompletionOct 1, 2016
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 12.6 years ago

Interventions

Losartandrug

Losartan will be given in increasing doses to those in the losartan arm.

Placebodrug

Placebo will be given to those in placebo arm